Following on from information provided to NICE by the company in December 2021, the appraisal of Tanezumab for treating pain caused by bone metastases [ID3784] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 3784 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 23 November 2022 | Discontinued. Following on from information provided to NICE by the company in December 2021, the appraisal of Tanezumab for treating pain caused by bone metastases [ID3784] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 15 December 2021 | Suspended. As you will be aware the Department for Health and Social Care has asked NICE to conduct an appraisal of tanezumab for treating pain caused by bone metastases. However, the company have advised that the European Medicines Agency Committee for Medicinal Products (CHMP) have issued a negative opinion for the Tanezumab marketing authorization application in the osteoarthritis indication. The company has therefore decided to discontinue the global clinical development programme for Tanezumab as a whole which includes treatment of pain caused by bone metastases. Therefore, NICE has decided to suspend this appraisal from its work program. As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes. |
For further information on our processes and methods, please see our CHTE processes and methods manual